Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | POLG | P54098 | 1/20 | 0.32 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18034250 | 1.00 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17426454 | 0.87 | LMNA (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17417844 | 0.87 | LMNA (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL16243285 | 0.86 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17426455 | 0.85 | LMNA (0.33) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2520518 | 0.85 | ENTPD2 (0.34) | — | |
| SCHEMBL12212795 | 0.85 | ENTPD2 (0.34) | — | |
| SCHEMBL16243281 | 0.85 | LMNA (0.34) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL26882783 | 0.84 | LMNA (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17417836 | 0.82 | LMNA (0.31) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006293-B1 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | TOKYO INST TECH (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-8039611-B2 | 2′-hydroxyl group-modified ribonucleoside derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100016574-A1 | 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2006293-A9 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-2006293-A2 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | Tokyo Institute of Technology (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016574-A1 | 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives | RNASEH1, RNASEL, NSUN2 | LMNA 673/4885THRB 1592/4885MTOR 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.